Perifosine is an alkylphospholipid compound primarily investigated for its anticancer properties. It functions by inhibiting key signaling pathways involved in cell survival and proliferation, particularly the PI3K/AKT pathway, which is often dysregulated in various cancers. This makes it a potential therapeutic agent in oncology, especially for tumors resistant to conventional treatments.

It has been studied in clinical trials for multiple cancer types, including advanced solid tumors, colorectal cancer, and multiple myeloma. Perifosine shows synergistic effects when combined with other anticancer agents such as radiation, chemotherapy, and targeted therapies, enhancing tumor cell sensitivity and apoptosis.

Due to its oral bioavailability and ability to cross cell membranes effectively, Perifosine offers a practical advantage in long-term cancer treatment regimens. Although clinical development has faced challenges due to variable efficacy and toxicity profiles, it remains of interest for targeted therapy approaches, particularly in patients with specific molecular tumor characteristics.